UK Wants Early Access Scheme To Remain ‘Relevant And Attractive’ Following Brexit
Proposals Aim To Reduce Burden Associated With Collecting Real-World Data
Executive Summary
The MHRA has drawn up measures to improve regulatory certainty around the UK’s early patient access scheme while reducing regulatory burden in certain areas of its operation.
You may also be interested in...
UK’s Early Access To Medicines Scheme To Get New Legal Basis
Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.
UK MHRA Aims To Cast Early Access Scheme In New Light
The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.
EMA Says Yes To BMS’ Sotyktu But Turns Down Ipsen’s Sohonos
The European Medicines Agency has recommended pan-EU marketing approval for four medicines but turned down Ipsen’s treatment for an ultra-rare bone disorder. It has also OK’d new uses of seven already-approved drugs and is reviewing efficacy concerns regarding Novartis’ sickle cell medicine.